Simcere Pharma (SCR) Misses Street's Q1 Views
Simcere Pharmaceutical Group (NYSE: SCR) reports Q1 EPS of $0.06, 11 cents lower than the analyst estimate of $0.17. Revenue for the quarter was $64.8 million, versus the consensus of $69.87 million.
You May Also Be Interested In
- UPDATE: Bristow Group (BRS) Reports Better-Than-Expected Q4 Results; Offers FY13 Outlook
- Rue21, Inc. (RUE) Tops Q1 EPS by 3c; Boosts FY12 EPS Outlook; Approves $50M Buyback
- AFC Enterprises, Inc. (AFCE) Tops Q1 EPS by 4c; Raises FY12 Comps Outlook
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
